latest news releases from the newsroom
ANTs Software, Inc.
ANTs Names Angelo Biscardi Director of Sales for Northeast Region
BURLINGAME, Calif., Jan. 13, 2004 (PRIMEZONE) -- ANTs Software Inc. (OTCBB:ANTS), a developer of high-performance SQL database management systems, announced today that it has named Angelo Biscardi as Director of Sales for Northeast Region, based in New York City. "Angelo brings to the company tremendous experience in enterprise sales, particularly in the financial services sector," said Steve Messino, Vice President of Sales. "This is a unique opportunity -- to join a company poised for tremendous growth. I am pleased to join the ANTs team and I am very enthusiastic to begin talking to potential customers about the benefits of the ANTs Data Server," said Mr. Biscardi.
Northrop Grumman Corp.
Northrop Grumman Delivers Composite Fuel Tank Half to NASA
EL SEGUNDO, Calif., Jan. 12, 2004 (PRIMEZONE) -- The viability of a reusable launch vehicle got a major technological boost recently when Northrop Grumman Corporation (NYSE:NOC) delivered the first composite fuel-tank structure to be made without using an autoclave. The new manufacturing process, which offers the promise of fuel tanks 10 to 25 percent lighter than comparably sized single-use aluminum tanks, would enable heavier payloads and lower operating costs for reusable space vehicles.
curasan AG: FDA approval for Cerasorb(R)DENTAL -- sales organization established
KLEINOSTHEIM, Germany, Jan. 13, 2004 (PRIMEZONE) -- The synthetic bone regeneration material Cerasorb(R)DENTAL, developed by curasan AG (WKN 549 453), is available for distribution within the US dental sector following a PMA (Premarket Approval) issued by the Food and Drug Administration (FDA). Thus, curasan is able to access the entire market for bone regeneration, as the company has already gained 510K approval for the area of orthopaedics and veterinary medicine.The Premarket Approval process is far more complex and protracted than a substantial-equivalence approval as part of the 510K procedure. One of the main advantages for the holder of a PMA is that competitors are not able to gain approval of their own products by simply referring to the approval dossier. This provides curasan with a lead over potential competitors.
Gastroenterological Expert to Join NutraCea Board of Directors
EL DORADO HILLS, Calif., Jan. 13, 2004 (PRIMEZONE) -- NutraCea (OTCBB:NTRZ), a leading nutraceutical research and development company, announced today that Eliot R. Drell, M.D. has agreed to join the company's board of directors. Dr. Drell has also been elected the chairman of NutraCea's medical advisory board, having previously served as a medical advisor for the company. Dr. Drell currently serves as a director for Gastroenterology Medical Clinic in Folsom, CA. He is also the president for UR Labs. Dr. Drell is also an active speaker and lecturer for major pharmaceutical companies, including Astra Zeneca (NYSE:AZN), Merck (NYSE:MRK) and Wyeth (NYSE:WYE).
Cecilia Kragsterman leaves Skandia
STOCKHOLM, Sweden, Jan. 13, 2004 (PRIMEZONE) -- Cecilia Kragsterman has been head of the Global Business Development unit and a member of the executive management team since January 2002. Due to changing market conditions and priorities within the company, management made the decision in the summer of 2003 to phase out the unit and transfer development work to the group's respective regions. The phase-out of Global Business Development has now been completed. In connection with this, Cecilia Kragsterman has decided to leave Skandia.
Tetra Pak denies allegations
STOCKHOLM, Sweden, Jan. 13, 2004 (PRIMEZONE) -- Tetra Pak will today provide its documentation of payments to Parmalat to the Italian authorities, to support them in their further investigation of Parmalat. Tetra Pak will also inform the authorities that all discount payments have gone to companies as directed by Parmalat.
Ahold Appeals to Shareholders
ZAANDAM, The Netherlands, Jan. 13, 2004 (PRIMEZONE) -- Ahold today appealed to the Association of Dutch Stockholders to discontinue the claims it has announced against Ahold. These claims are not in the interests of shareholders.